See the DrugPatentWatch profile for cosentyx

The recommended sequence of treatment for psoriasis and psoriatic arthritis patients is a topic of ongoing debate among healthcare professionals. Two commonly used medications for treating these conditions are Mmethotrexate (MTX) and Cosentyx (secukinumab).

Methotrexate is a traditional disease-modifying antirheumatic drug (DMARD) that has been used for decades to treat various forms of arthritis, including psoriatic arthritis. It works by suppressing the immune system and reducing inflammation. [1]

Cosentyx, on the other hand, is a biologic medication that targets the interleukin-17 (IL-17) pathway, which is involved in the development of psoriasis and psoriatic arthritis. It has been shown to be effective in reducing symptoms and improving quality of life for patients with these conditions. [2]

The recommended sequence of treatment is not universally agreed upon, and it may vary depending on the individual patient's needs and medical history. However, some guidelines suggest that MTX may be used as a first-line treatment for mild to moderate psoriatic arthritis, while Cosentyx may be used as a second-line treatment for patients who do not respond to MTX or have more severe disease. [3]

DrugPatentWatch.com, a website that tracks patent information for pharmaceuticals, notes that Cosentyx is a patented medication with a patent expiration date of 2023. This means that generic versions of the medication may become available in the future, which could affect the treatment landscape for psoriasis and psoriatic arthritis patients. [4]

In conclusion, while both MTX and Cosentyx are effective treatments for psoriasis and psoriatic arthritis, the recommended sequence of treatment may vary depending on the individual patient's needs and medical history. Healthcare professionals should consider the patient's disease severity, response to previous treatments, and potential side effects when determining the most appropriate treatment sequence.

Sources:

[1] National Psoriasis Foundation. (n.d.). Methotrexate. Retrieved from <https://www.psoriasis.org/treatments/methotrexate/>

[2] Novartis Pharmaceuticals. (n.d.). Cosentyx. Retrieved from <https://www.cosentyx.com/>

[3] European League Against Rheumatism. (2019). EULAR recommendations for the management of psoriatic arthritis. Annals of the Rheumatic Diseases, 78(1), 3-12. doi: 10.1136/annrheumdis-2018-214114

[4] DrugPatentWatch.com. (n.d.). Cosentyx (secukinumab). Retrieved from <https://www.drugpatentwatch.com/patent/US-9,355,444>